论文部分内容阅读
目的卡培他滨(希罗达)治疗晚期乳腺癌的疗效分析和不良反应。方法选择濮阳市油田总医院2012年6月至2013年6月收治的晚期乳腺癌患者120例,应用卡培他滨1500mg/m2进行治疗,每2d服用1次,持续服用3周,每三周作为一个周期,每周期之间患者休息一周,治疗2个周期后对治疗效果进行评估分析。结果本组120例患者中25例患者病情完全缓解(CR),56患者部分缓解(PR),19例患者病情稳定(SD),10例患者为进展(PD)。卡培他滨治疗有效率61.67%,中位无进展生存期为7.8个月。患者治疗过程中出现了腹泻,恶心呕吐,白细胞减少,血小板降级,身体出现大量色素沉积等不良反应,以上不良反应均为I-II度,患者可以耐受。结论卡培他滨(希罗达)治疗晚期乳腺癌的疗效显著,不良反应较轻,患者可以耐受。
Objective To analyze the curative effect and adverse reactions of capecitabine (Xeloda) in the treatment of advanced breast cancer. Methods 120 patients with advanced breast cancer who were treated in Puyang Oilfield General Hospital from June 2012 to June 2013 were treated with capecitabine 1500mg / m2, taken once every 2 days for 3 weeks, every 3 weeks As a cycle, patients take a week off each week, after treatment for 2 cycles to assess the effect of treatment. Results Of the 120 patients in this study, 25 patients achieved complete remission (CR), 56 had partial remission (PR), 19 had stable disease (SD), and 10 patients had progressed (PD). Capecitabine treatment efficiency 61.67%, median progression-free survival of 7.8 months. Patients with diarrhea, nausea and vomiting, leukopenia, platelet degeneration, the body appeared a large number of adverse reactions such as pigmentation, the above adverse reactions are I-II degrees, the patient can tolerate. Conclusion Capecitabine (Xeloda) treatment of advanced breast cancer significant effect, less adverse reactions, patients can tolerate.